Replies to post #221623 on Biotech Values

[tika1]

What is point to continuing testing if it failed at OS and PFS? Why are they wasting $$ which they don't have?

[DewDiligence]

SNDX -12%/AH on Entinostat failures in ovarian and TNBC:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-fourth-quarter-2018-financial-results-and-provides-clinical-and-business-update-300808834.html

The Phase 1b/2 ENCORE 603 trial, which evaluated entinostat in combination with avelumab in patients with heavily pretreated advanced epithelial ovarian cancer, and the Phase 1b/2 ENCORE 602 trial, which evaluated entinostat in combination with atezolizumab in patients with PD-1 naïve, previously treated TNBC, each failed to meet its respective primary endpoint of a statistically significant improvement in PFS.